Addressing Key Questions: Expert Insights to Guide Pathologist-Informed Clinical Decisions in HER2-Expressing or Amplified Solid Tumors

Download slides, watch an on-demand webcast, and review a short commentary from a live symposium at USCAP 2024 in which a panel of pathologists and medical oncologists discussed the nuances of HER2 testing across solid tumors and the impact of testing results on treatment selection.

Share

Program Content

Activities

HER2 Testing in Solid Tumors
Expert Insights Into HER2 Testing for Advanced Breast, GI, and Lung Cancers
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 25, 2024

Expires: March 24, 2025

HER2 Targeted Therapy in Solid Tumors
Applying HER2 Testing Results to Treatment Decisions for Patients With Solid Tumors
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 25, 2024

Expires: March 24, 2025

Activities

Pathological Decisions in HER2 Tumors
Addressing Key Questions: Expert Insights to Guide Pathologist-Informed Clinical Decisions in HER2-Expressing or Amplified Solid Tumors
Video
Congratulations: You achieved a completion on 04/09/2022

Released: April 10, 2024

Expires: April 09, 2025

Activities

HER2 Pathology Insights
Expert Insights Into How Pathologists Can Guide Clinical Decision-making for HER2-Altered Solid Tumors
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: April 23, 2024

Expires: April 22, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Jazz Pharmaceuticals, and Seagen.

AstraZeneca

Daiichi Sankyo, Inc.

Jazz Pharmaceuticals

Seagen